159 related articles for article (PubMed ID: 20839031)
1. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
4. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
5. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada A; Gil T; Whenham N; Van Hamme J; Besse-Hammer T; Brendel E; Delesen H; Joosten MC; Lathia CD; Loembé BA; Piccart-Ghebart M; Hendlisz A
J Clin Pharmacol; 2011 Dec; 51(12):1674-84. PubMed ID: 21209247
[TBL] [Abstract][Full Text] [Related]
9. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Jansen EP; Boot H; Dubbelman R; Bartelink H; Cats A; Verheij M
Br J Cancer; 2007 Sep; 97(6):712-6. PubMed ID: 17848909
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
Trials; 2013 Jul; 14():228. PubMed ID: 23876062
[TBL] [Abstract][Full Text] [Related]
11. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
12. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Infante JR; Jones SF; Bendell JC; Greco FA; Yardley DA; Lane CM; Spigel DR; Hainsworth JD; Burris HA
Cancer Chemother Pharmacol; 2012 Jan; 69(1):137-44. PubMed ID: 21626051
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Martin-Richard M; Gallego R; Pericay C; Garcia Foncillas J; Queralt B; Casado E; Barriuso J; Iranzo V; Juez I; Visa L; Saigi E; Barnadas A; Garcia-Albeniz X; Maurel J
Invest New Drugs; 2013 Dec; 31(6):1573-9. PubMed ID: 24077981
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Lee KW; Park SR; Oh DY; Park YI; Khosravan R; Lin X; Lee SY; Roh EJ; Valota O; Lechuga MJ; Bang YJ
Invest New Drugs; 2013 Dec; 31(6):1547-58. PubMed ID: 24091982
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Rao S; Starling N; Cunningham D; Benson M; Wotherspoon A; Lüpfert C; Kurek R; Oates J; Baselga J; Hill A
Br J Cancer; 2008 Sep; 99(6):868-74. PubMed ID: 19238629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]